| LDL-cholesterol, HDL-cholesterol or triglycerides--which is the culprit? | |
| | |
MedLine Citation:
|
PMID: 12880691 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Dyslipidaemia in patients with type 2 diabetes commonly consists of elevated triglyceride levels; normal or slightly elevated low-density lipoprotein (LDL)-cholesterol levels with a preponderance of small, dense LDL particles; and low high-density lipoprotein (HDL)-cholesterol levels with a preponderance of small, dense HDL. These abnormalities are closely connected, with prolonged residence of high levels of triglyceride-rich particles in the circulation favoring abnormalities in LDL and HDL. Each of these factors has been associated with endothelial dysfunction; each contributes directly or indirectly to atheroma formation, with small, dense LDL and triglyceride-rich remnants increasing deposition of cholesteryl ester in vessel walls. This process is facilitated by reduced reverse cholesterol transport in association with low levels of HDL-cholesterol and abnormal HDL. Lipid-lowering therapy focused on LDL-cholesterol reduction is highly successful in preventing coronary disease in diabetic patients. Additional strategies for treating the cluster of risk factors in dyslipidaemia are necessary to further reduce atherosclerotic disease in this population. |
| | |
Authors:
|
Marja Riitta Taskinen |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Diabetes research and clinical practice Volume: 61 Suppl 1 ISSN: 0168-8227 ISO Abbreviation: Diabetes Res. Clin. Pract. Publication Date: 2003 Jul |
Date Detail:
|
Created Date: 2003-07-25 Completed Date: 2004-04-23 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8508335 Medline TA: Diabetes Res Clin Pract Country: Ireland |
Other Details:
|
Languages: eng Pagination: S19-26 Citation Subset: IM |
Affiliation:
|
Division of Cardiology, Department of Medicine, University of Helsinki, Biomedicum, Haartmaninkatu 8, Helsinki 00290, Finland. mataskin@helsinki.fi |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antilipemic Agents
/
therapeutic use Arteriosclerosis / blood*, complications Cholesterol, HDL / blood* Cholesterol, LDL / blood* Clofibric Acid / analogs & derivatives*, therapeutic use Controlled Clinical Trials as Topic Coronary Disease / blood, etiology, prevention & control Diabetes Mellitus, Type 2 / blood, complications Humans Particle Size Risk Factors Sex Factors Triglycerides / blood* |
| Chemical | |
Reg. No./Substance:
|
0/Antilipemic Agents; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Triglycerides; 52214-84-3/ciprofibrate; 882-09-7/Clofibric Acid |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Pre-diabetes, insulin resistance, inflammation and CVD risk.
Next Document: Reducing coronary heart disease associated with type 2 diabetes: lifestyle intervention and treatmen...